Unfortunately, a phase 2 study of abemaciclib in 23 melanoma patients with intracranial metastases showed 0% objective responses, but patients were selected irrespective of the presence of the CDKN2A pathway alteration [139]. The gene discussed is CDKN2A; the disease is melanoma.